-+ 0.00%
-+ 0.00%
-+ 0.00%

Xinhua Pharmaceutical announced that the OAB-14 dry suspension to treat mild to moderate Alzheimer's disease has completed the enrollment of the first Chinese patient in phase II clinical trials. The OAB-14 dry suspension phase II drug clinical trial involved the participation of Xuanwu Hospital of Capital Medical University and multiple centers across the country to complete the enrollment of the first Chinese patient on June 19, 2025. OAB-14 is an innovative drug with a new chemical structure developed by Xinhua Pharmaceutical in collaboration with Shenyang Pharmaceutical University with independent intellectual property rights. It is a Class 1 innovative drug.

Zhitongcaijing·06/19/2025 08:25:02
Listen to the news
Xinhua Pharmaceutical announced that the OAB-14 dry suspension to treat mild to moderate Alzheimer's disease has completed the enrollment of the first Chinese patient in phase II clinical trials. The OAB-14 dry suspension phase II drug clinical trial involved the participation of Xuanwu Hospital of Capital Medical University and multiple centers across the country to complete the enrollment of the first Chinese patient on June 19, 2025. OAB-14 is an innovative drug with a new chemical structure developed by Xinhua Pharmaceutical in collaboration with Shenyang Pharmaceutical University with independent intellectual property rights. It is a Class 1 innovative drug.